LLY

Eli Lilly and Company [LLY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LLY Stock Summary

Top 10 Correlated ETFs

LLY


Top 10 Correlated Stocks

LLY


In the News

04:34 29 Sep 2023 LLY

US judge overturns Eli Lilly's $176.5 million loss in Teva patent case

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.

01:00 29 Sep 2023 LLY

Don't Miss the Boom: 3 Biotech Stocks Set to Explode Higher

In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.

01:00 29 Sep 2023 LLY

2 Magnificent Dividend Stocks to Buy Right Now

High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.

01:32 29 Sep 2023 LLY

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

10:31 29 Sep 2023 LLY

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

08:30 29 Sep 2023 LLY

The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.

06:50 29 Sep 2023 LLY

3 Magnificent Growth Stocks to Buy Right Now

Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.

04:00 29 Sep 2023 LLY

David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′

The so-called “Magnificent 7” stocks surged in 2023, contributing to a market rebound in an outsized manner. The stocks' presumed overrepresentation has investors considering other investments in their place.

05:05 29 Sep 2023 LLY

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend

Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks to the growing implementation of artificial intelligence ( AI ), upending the field and bringing big changes to the industry.

09:45 29 Sep 2023 LLY

Are Wall Street Analysts Wrong About Eli Lilly Stock?

After massive gains this year, Eli Lilly's stock has eclipsed many analysts' price targets. Still, the drugmaker has huge growth potential from its current product lineup.

LLY Financial details

Company Rating
Strong Buy
Market Cap
522.62B
Income
6.5B
Revenue
29.52B
Book val./share
12.3
Cash/share
3.14
Dividend
4.37
Dividend %
0.79%
Employees
39K
Optionable
Yes
Shortable
Yes
Earnings
02 Nov 2023
P/E
76.12
Forward P/E
-
PEG
49.28
P/S
17.68
P/B
44.71
P/C
172.68
P/FCF
162.51
Quick Ratio
0.63
Current Ratio
1.13
Debt / Equity
1.7
LT Debt / Equity
1.64
-
-
EPS (TTM)
7.1
EPS next Y
-
EPS next Q
2.44
EPS this Y
12.68%
EPS next Y
-
EPS next 5Y
40.07%
EPS last 5Y
17.15%
Revenue last 5Y
5.84%
Revenue Q/Q
19.43%
EPS Q/Q
31.54%
-
-
-
-
SMA20
0.18%
SMA50
23.39%
SMA100
33.17%
Inst Own
86.42%
Inst Trans
0.94%
ROA
12%
ROE
60%
ROC
0.21%
Gross Margin
78%
Oper. Margin
25%
Profit Margin
22%
Payout
59%
Shs Outstand
949.29M
Shs Float
897.49M
-
-
-
-
Target Price
387.71
52W Range
304.88-601.84
52W High
-9.78%
52W Low
+78.36%
RSI
43
Rel Volume
0.53
Avg Volume
2.91M
Volume
1.55M
Perf Week
-4.82%
Perf Month
0.84%
Perf Quarter
47.74%
Perf Half Y
62.04%
-
-
-
-
Beta
0.315006
-
-
Volatility
2.99%, 16.73%
Prev Close
-1.38%
Price
542.2
Change
-1.4%

LLY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
20.9123.9727.0431.2231.65
Net income per share
3.144.986.826.156.93
Operating cash flow per share
5.385.197.168.017.86
Free cash flow per share
2.443.744.935.945.1
Cash per share
7.212.624.064.312.45
Book value per share
9.562.86.229.911.81
Tangible book value per share
8.25-8.16-5.94-2.68-0.56
Share holders equity per share
9.562.86.229.911.81
Interest debt per share
10.2917.418.6818.9918.38
Market cap
118.93B122.37B153.24B250.52B329.89B
Enterprise value
121.91B135.84B166.18B263.59B344.06B
P/E ratio
36.826.3824.7444.8852.83
Price to sales ratio
5.535.486.248.8511.56
POCF ratio
21.5325.323.5834.546.57
PFCF ratio
47.4535.1334.2846.571.71
P/B Ratio
12.146.9427.1627.930.98
PTB ratio
12.146.9427.1627.930.98
EV to sales
5.676.096.779.3112.05
Enterprise value over EBITDA
12.6420.5721.7530.1636.47
EV to operating cash flow
22.0728.0825.5736.348.57
EV to free cash flow
48.643937.1748.9374.79
Earnings yield
0.030.040.040.020.02
Free cash flow yield
0.020.030.030.020.01
Debt to equity
1.056.062.941.881.52
Debt to assets
0.230.40.360.350.33
Net debt to EBITDA
0.312.041.691.51.5
Current ratio
1.731.161.41.231.05
Interest coverage
22.7412.4216.8518.7121.49
Income quality
1.710.581.051.31.13
Dividend Yield
0.020.020.020.010.01
Payout ratio
0.720.520.430.550.57
Sales general and administrative to revenue
0.280.280.250.230.23
Research and developement to revenue
0.240.250.250.250.25
Intangibles to total assets
0.060.260.240.240.23
Capex to operating cash flow
-0.55-0.28-0.31-0.26-0.35
Capex to revenue
-0.14-0.06-0.08-0.07-0.09
Capex to depreciation
-1.88-1.1-1.53-1.21-1.63
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
26.0117.7130.8937.0342.9
ROIC
0.260.230.230.220.24
Return on tangible assets
0.080.160.170.150.16
Graham Net
-19.18-30.5-32.99-30.55-30.97
Working capital
8.66B1.93B4.98B3.4B896.3M
Tangible asset value
8.47B-7.6B-5.39B-2.43B-504.2M
Net current asset value
-12.45B-22.88B-23.35B-21.2B-20.68B
Invested capital
1.056.062.941.881.52
Average receivables
5.52B5.66B6.24B7.53B8.34B
Average payables
1.31B1.31B1.51B1.64B1.8B
Average inventory
3.78B3.14B3.59B3.93B4.1B
Days sales outstanding
98.190.62103.06104.75109.45
Days payables outstanding
94.11108.64106.9583.38106.29
Days of inventory on hand
241.54246.68264.95193.96237.27
Receivables turnover
3.724.033.543.483.33
Payables turnover
3.883.363.414.383.43
Inventory turnover
1.511.481.381.881.54
ROE
0.331.781.10.620.59
Capex per share
-2.94-1.45-2.24-2.07-2.75

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
7.217.717.687.719.24
Net income per share
1.061.612.041.491.96
Operating cash flow per share
0.912.431.661.920.7
Free cash flow per share
0.411.741.080.92-0.23
Cash per share
3.043.042.334.063.14
Book value per share
9.4911.1811.2112.3912.3
Tangible book value per share
-3.03-0.94-0.530.150.19
Share holders equity per share
9.4911.1811.2112.3912.3
Interest debt per share
18.7717.7317.1821.0221.05
Market cap
291.9B291.24B347.61B310.21B421.94B
Enterprise value
306.1B304.51B361.79B325.54B438.07B
P/E ratio
76.6250.1644.8557.6659.83
Price to sales ratio
44.9941.9647.6144.5750.76
POCF ratio
355.68133.3220.05179.25667.73
PFCF ratio
789.57186.14339.43375.05-2.06K
P/B Ratio
34.1628.9232.6427.7238.14
PTB ratio
34.1628.9232.6427.7238.14
EV to sales
47.1843.8749.5546.7752.7
Enterprise value over EBITDA
147.14126.77151.2191.05188.83
EV to operating cash flow
372.97139.38229.02188.11693.25
EV to free cash flow
827.96194.63353.27393.6-2.14K
Earnings yield
000.0100
Free cash flow yield
00.01000
Debt to equity
1.971.581.521.691.7
Debt to assets
0.360.330.330.360.34
Net debt to EBITDA
6.825.525.9296.95
Current ratio
1.11.131.051.31.13
Interest coverage
21.3225.0221.8614.5317.67
Income quality
0.861.50.821.290.36
Dividend Yield
00000
Payout ratio
0.930.610.460.760.58
Sales general and administrative to revenue
0.240.220.230.250.23
Research and developement to revenue
0.270.260.270.290.28
Intangibles to total assets
0.240.230.230.210.2
Capex to operating cash flow
-0.55-0.28-0.35-0.52-1.32
Capex to revenue
-0.07-0.09-0.08-0.13-0.1
Capex to depreciation
-1.29-1.71-1.48-2.49-2.28
Stock based compensation to revenue
0.010.010.010.020.02
Graham number
15.0320.1422.6820.3723.29
ROIC
0.060.070.060.040.06
Return on tangible assets
0.030.040.050.030.04
Graham Net
-31.06-29.3-29.39-32.28-35.08
Working capital
1.49B1.99B896.3M4.8B2.42B
Tangible asset value
-2.73B-849.8M-504.2M134.7M166.9M
Net current asset value
-21.29B-19.66B-20.68B-21.06B-22.33B
Invested capital
1.971.581.521.691.7
Average receivables
7.74B8B8.44B8.79B9.1B
Average payables
1.55B1.67B1.81B1.97B2.25B
Average inventory
3.9B3.87B4.07B4.43B4.67B
Days sales outstanding
106.43107.93105.49116.6799.3
Days payables outstanding
104.3995.93112.24111.53123.2
Days of inventory on hand
245.33218.35250.55251.45238.95
Receivables turnover
0.850.830.850.770.91
Payables turnover
0.860.940.80.810.73
Inventory turnover
0.370.410.360.360.38
ROE
0.110.140.180.120.16
Capex per share
-0.5-0.69-0.58-1-0.93

LLY Frequently Asked Questions

What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY

Is Eli Lilly and Company buy or a sell ?

42 stock analysts have 42 predictions with a medium analyst target price of $366.48. The lowest prediction is $236 and the highest is $630

What is LLY stock prediction ?

With a median analyst target price of $623.5, 2 stock analysts have made 2 forecasts in last 90 days. $617 is the lowest and $630 is the greatest projection.

What is Eli Lilly and Company stock quote today ?

Eli Lilly and Company stock price is $542.2 today.

Is Eli Lilly and Company stock public?

Yes, Eli Lilly and Company is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks